Remove

Pages, Columns, Lines where

Ţ5

	Application Number		09801495		
	Filing Date		2001-03-08		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Keith			
	Art Unit		3693		
	Examiner Name	Richard C. Weisberger			
	Attorney Docket Numb	er	125466		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where vant Passages or Releves es Appear	
	1									
If you wisl	h to ad	d additional U.S. Pater	t citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT /	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite N	o Publication Number	Kind Code <sup>1</sup>	Publicat Date	ion	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where vant Passages or Releves es Appear	
	1									
If you wisl	h to ad	d additional U.S. Publis	hed Ap	plication	citation	n information p	lease click the Add	d butto	n. Add	
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*			Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate) title of the item										

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

Examiner Cite

Initials\* No

#### 

1	*SEC Tells Markets to Start Transition to Decimal Pricing, Securities: Stocks, Options Can Be Quoted in Increments of 5 Cents, Change From Fractions Must Be Complete by Year-End., [Home Edition].* Los Angeles Times, Los Angeles, Calif., January 29, 2000, page C.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kiss Codes of USPTO Patient Documents at sure USPTO\_GOU or MECP 901.64. <sup>2</sup> Enter office that issued the document, by the No-letter code (NIPO) Standard 37.3. <sup>3</sup> For Supparent patient columents, the natication of the year of the right of the Emperor must perceive the serial number of the patient document.

\* Nint of coursent by the appropriate symbols as indicated on the document under WIPO Standard 37.1.6 if possible. <sup>1</sup> Applicant is to place a check mark there is received in the document to the do

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09801495	
Filing Date		2001-03-08	
First Named Inventor	Keth		
Art Unit		3693	
Examiner Name	Richa	Richard C. Weisberger	
Attorney Docket Number		125466	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

Kevan L. Morgan

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	form of the signature.			
ı	Signature	/Keyan L. Morgan/	Date (YYYY-MM-DD)	2012-11-15

Registration Number

42015

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of December 1.00 and 1.00 Accessed, New York 1.00 Accessed 1.00 Ac

Name/Print

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested private information is used to be added to the process and the process of the process of the process of the private information of the patient of the process o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552(am).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.